Neal Shore, MD, FACS, emphasizes the significance of the VISION and TheraP trials in supporting the FDA approval of Lutetium-177 for patients with mCRPC who have undergone androgen receptor inhibitor ...

"Aquablation is like no other transurethral therapy that has come about in the last 100 years," says Ravi Munver, MD. In this video, Ravi Munver, MD, discusses the real-time, ultrasound-guided ...

A 4-gene signature (ATM, RB1, FANCC, ERCC2) correlates with tumor absence post-neoadjuvant chemotherapy in muscle-invasive bladder cancer. The biomarker is more effective at predicting disease ...

UTUC is a rare malignancy, primarily affecting older men, with smoking as a significant risk factor. Nephron-sparing approaches are gaining interest due to complications from nephroureterectomy and ...

Steerable suction catheters and scopes are revolutionizing stone disease surgery, enhancing safety and efficiency. The MONARCH trial and CVAC scope are key innovations in stone removal, allowing ...

Nivolumab addition to standard therapy improved 2-year FFBR to 90.3%, surpassing the historical control rate of 75%. The study cohort showed significant FFBR improvement over the contemporary control ...

SBRT shows promise in achieving progression-free survival in metastatic RCC without systemic therapy, despite limited high-level data. The absence of phase 3 trials leaves a gap in comparing SBRT ...

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

Prostate cancer patients have a higher depression incidence (10%-40%) than the general population (9%). Racial disparities exist in depression diagnosis and treatment ...

Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

"If the documentation supported the use of modifier –22, it should be appended," write Jonathan Rubenstein, MD, and Mark Painter. As with most cases, we need to start with a review of the ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...